Phaseline

Companies › Katmai Pharmaceuticals

Katmai Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ERAS-801–Phase 1Glioblastoma Multiforme; Glioblastoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05222802ERAS-801Phase 1Glioblastoma MultiformeOncologyAug 2025
NCT06934889ERAS-801Phase 1GlioblastomaOncologyApr 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.